Segment Reporting (Tables)

12 Months Ended

Jun. 30, 2026

Disclosure of operating segments [abstract]

Schedule of Segment Information for the Reportable Segments

The segment information for the reportable segments for the year ended June 30, 2026 is as follows:

		Research and development				Hyper-immune products				Corporate				Total
2026		A$				A$				A$				A$
Hyper-immune products revenue			-				7,713,601				-				7,713,601
Cost of sales of goods			-				(2,738,529	)			-				(2,738,529	)
Gross profit			-				4,975,072				-				4,975,072
Other income			1,122,132				47,737				-				1,169,869
Net foreign exchange gains/(losses)			-				-				(285,115	)			(285,115	)
Movement in inventory provision			-				-				-				-
General and administrative expenses			-				-				(4,305,555	)			(4,305,555	)
Research and development expenses			(1,933,440	)			-				-				(1,933,440	)
Selling and marketing expenses			-				(3,471,556	)			-				(3,471,556	)
Operating profit/(loss)			(811,308	)			1,551,253				(4,590,670	)			(3,850,725	)
Finance income			-				-				185,438				185,438
Finance costs			-				-				(14,712	)			(14,712	)
Share of loss from associates			-				-				-				-
Profit/(loss) for the year			(811,308	)			1,551,253				(4,419,944	)			(3,679,999	)
Assets
Segment assets			782,313				2,900,653				9,468,732				13,151,698
Total assets			782,313				2,900,653				9,468,732				13,151,698
Liabilities
Segment liabilities			179,995				744,280				1,062,396				1,986,671
Total liabilities			179,995				744,280				1,062,396				1,986,671

The segment information for the reportable segments for the year ended June 30, 2025 is as follows:

		Research and development				Hyper-immune products				Corporate				Total
2025		A$				A$				A$				A$
Hyper-immune products revenue			-				7,287,002				-				7,287,002
Cost of sales of goods			-				(2,521,903	)			-				(2,521,903	)
Gross profit			-				4,765,099				-				4,765,099
Other income			1,380,993				30,512				-				1,411,505
Net foreign exchange gains/(losses)			-				-				12,183				12,183
General and administrative expenses			(562,960	)			-				(3,920,663	)			(4,483,623	)
Research and development expenses			(3,597,296	)			-				-				(3,597,296	)
Selling and marketing expenses			-				(3,452,416	)			-				(3,452,416	)
Operating profit/(loss)			(2,779,263	)			1,343,195				(3,908,480	)			(5,344,548	)
Finance income			-				-				135,866				135,866
Finance costs			-				-				(7,305	)			(7,305	)
Profit/(loss) for the year			(2,779,263	)			1,343,195				(3,779,919	)			(5,215,987	)

Assets
Segment assets			1,110,514				1,737,563				7,281,765				10,129,842
Total assets			1,110,514				1,737,563				7,281,765				10,129,842

Liabilities
Segment liabilities			230,875				617,461				1,212,451				2,060,787
Total liabilities			230,875				617,461				1,212,451				2,060,787

The segment information for the reportable segments for the year ended June 30, 2024 is as follows:

		Research and development				Hyper-immune products				Corporate				Total
2024		A$				A$				A$				A$
Hyper-immune products revenue			-				4,902,865				-				4,902,865
Cost of sales of goods			-				(1,566,068	)			-				(1,566,068	)
Gross profit			-				3,336,797				-				3,336,797
Other income			3,364,439				43,760				-				3,408,199
Fair value losses to financial assets			-				-				(557,676	)			(557,676	)
Net foreign exchange gains/(losses)			-				-				(27,603	)			(27,603	)
General and administrative expenses			(460,251	)			(3,565	)			(4,091,910	)			(4,555,726	)
Research and development expenses			(5,375,461	)			-				-				(5,375,461	)
Selling and marketing expenses			-				(2,029,648	)			-				(2,029,648	)
Operating profit/(loss)			(2,471,273	)			1,347,344				(4,677,189	)			(5,801,118	)
Finance income			-				-				327,756				327,756
Finance costs			-				-				(7,576	)			(7,576	)
Share of loss from associates			-				-				(1,456,019	)			(1,456,019	)
Profit/(loss) for the year			(2,471,273	)			1,347,344				(5,813,028	)			(6,936,957	)
Assets
Segment assets			768,370				2,845,096				11,936,503				15,549,969
Total assets			768,370				2,845,096				11,936,503				15,549,969
Liabilities
Segment liabilities			604,018				206,524				2,029,983				2,840,525
Total liabilities			604,018				206,524				2,029,983				2,840,525

Schedule of Major Product Lines and Geographical Regions

The group derives revenue from the transfer of hyper-immune products at a point in time in the following major product lines and geographical regions:

		Travelan												ProIBS				Protectyn
		Australia				United States				Canada				Australia				Australia				Total
2026		A$				A$				A$				A$				A$				A$
Hyper-immune products revenue			5,672,502				1,768,411				165,668				85,221				21,799				7,713,601
Revenue from external customers			5,672,502				1,768,411				165,668				85,221				21,799				7,713,601

		Travelan												Protectyn
		Australia				United States				Canada				Australia				Total
2025		A$				A$				A$				A$				A$
Hyper-immune products revenue			5,201,385				1,658,336				378,706				48,575				7,287,002
Revenue from external customers			5,201,385				1,658,336				378,706				48,575				7,287,002

		Travelan												Protectyn
		Australia				United States				Canada				Australia				Total
2024		A$				A$				A$				A$				A$
Hyper-immune products revenue			3,702,876				1,075,614				80,888				43,487				4,902,865
Revenue from external customers			3,702,876				1,075,614				80,888				43,487				4,902,865

Schedule of Major Customers

During the years ended June 30, 2026, 2025 and 2024, the Company had the following major customers in the hyper-immune product segment with revenues amounting to 10 percent or more of total group revenues:

		2026 A$				2025 A$				2024 A$
Customer A			4,199,953				3,272,556				2,308,425
Customer B			1,239,030				1,558,156				957,076
Customer C			1,045,802				958,031				842,173
Customer D			977,392				860,086				552,509
			7,462,177				6,648,829				4,660,183